Value Sense
AMGN
Amgen Inc. (AMGN)
Last Price$324.92.2%
Market Cap$175.6B
Intrinsic value score
6/10
Good
Intrinsic value
$461.6
DCF value - $665.7 Relative value - $257.5
Undervalued
42.1%
LTM P/E
42.9x
Peer set median 28.5x
Discount rate
5.4%
AMGN
is 42.1% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

AMGN Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 07, 2025 AMGN Relative Value is $257.2, which is overvalued by 20.8%, compared to current share price of $324.9.
DCF Value vs Current Share Price
As of Mar 07, 2025 AMGN DCF Value is $667.9, which is undervalued by 105.6%, compared to current share price of $324.9.
Methodology
Price per share, $
AMGN
Intrinsic value$461.6
Undervalued by42.1%
Current share price
324.9
Relative value
257.2
DCF value
667.9

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

AMGN Historical Intrinsic Value

Crunching data... Almost there!

AMGN vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Amgen Inc. logo
Amgen Inc.AMGN
42.1%
18.6%
(39.8%)
12.2%
Median Peer Set
6.7%
(5.7%)
12.6%
Eli Lilly and Company logo
Eli Lilly and CompanyLLY
(75.3%)
32.0%
102.4%
23.5%
Sanofi logo
SanofiSNY
(36.5%)
(3.8%)
3.1%
12.6%
AstraZeneca PLC logo
AstraZeneca PLCAZN
(23.0%)
18.0%
135.9%
13.0%
Gilead Sciences, Inc. logo
Gilead Sciences, Inc.GILD
(15.8%)
6.0%
(91.6%)
1.7%
Novartis AG logo
Novartis AGNVS
18.6%
10.8%
(16.5%)
23.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.8%
4.3%
(57.9%)
15.8%
Merck & Co., Inc. logo
Merck & Co., Inc.MRK
25.3%
1.4%
(97.6%)
0.6%
Pfizer Inc. logo
Pfizer Inc.PFE
54.4%
8.8%
273.7%
12.6%
AbbVie Inc. logo
AbbVie Inc.ABBV
56.3%
3.7%
(11.4%)
7.6%
Bristol-Myers Squibb Company logo
Bristol-Myers Squibb CompanyBMY
81.3%
7.3%
N/A
(18.5%)

Explore more intrinsic value tools hub for AMGN

DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate

FAQ

What is Amgen Inc. intrinsic value?

As of Mar 07, 2025, Amgen Inc. Intrinsic Value is $461.6. This suggests it may be undervalued by 42.1% compared to its current price of around $324.9.

What is Amgen Inc. DCF (discounted cash flow) valuation?

As of Mar 07, 2025, Amgen Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $667.9. This suggests it may be overvalued by 105.6% to its current price of around $324.9, using a discount rate of 5.4% and terminal growth rate of 3.0%.

Is Amgen Inc. overvalued or undervalued?

Amgen Inc. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $461.6, compared to a market price of around $324.9. This suggests a potential undervaluation of 42.1%.